SIRT1 rs3758391 polymorphism and risk of diffuse large B cell lymphoma in a Chinese population
Open Access
- 22 October 2018
- journal article
- research article
- Published by Springer Nature in Cancer Cell International
- Vol. 18 (1) , 163
Abstract
The aim of the study was to explore the association between the SIRT1 single nucleotide polymorphism (SNP) rs3758391 and diffuse large B cell lymphoma (DLBCL) in a Chinese Han population. 206 patients diagnosed with DLBCL and 219 healthy individuals were recruited in the present study. The genotyping of SIRT1 rs3758391 polymorphism was detected by polymerase chain reaction–restriction fragment length polymorphism. The SIRT1 mRNA expression was detected by the Taqman real-time quantitative PCR. Our study showed that the genotype TT and allele T frequency were significantly higher in DLBCL patients than that of controls (p = 0.02 and 0.01, respectively). No statistical differences were observed between SIRT1 rs3758391 and clinical characteristics of DLBCL patients. Analysis of the polymorphism revealed an increased risk of DLBCL associated with TC and TT genotype when compared with CC genotype [odds ratio = 2.621 and 3.518, respectively; 95% confidence interval (CI) 1.249–5.501 and 1.675–7.390, respectively; p = 0.011 and 0.001, respectively]. The survival analysis indicated that the patients with C allele had higher overall survival rate than those with genotype TT (p = 0.005). Furthermore, multivariate Cox regression analysis showed that the TT genotype of SIRT1 SNP rs3758391 was an independent poor prognostic factor for DLBCL patients (p = 0.006, HR 1.981, 95% CI 1.215–3.231). The SIRT1 mRNA expression was significantly upregulated in DLBCL patients than that of controls (p < 0.001). In addition, the SIRT1 mRNA expression of TT subgroup was upregulated compared with TC/CC subgroup in DLBCL patients (p < 0.001). These results suggest that the SIRT1 rs3758391 polymorphism is associated with the risk and survival rate of DLBCL in Chinese Han population.Keywords
Funding Information
- National Natural Science Foundation of China (81100337, 81470283)
- Natural Science Foundation of Ningbo Municipality (2014A610229)
This publication has 31 references indexed in Scilit:
- Genetic Landscapes of Relapsed and Refractory Diffuse Large B-Cell LymphomasClinical Cancer Research, 2016
- An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab eraBlood, 2014
- The Roles of SIRT1 in CancerGenes & Cancer, 2013
- HATs and HDACs: from structure, function and regulation to novel strategies for therapy and preventionOncogene, 2007
- Mammalian sirtuins—emerging roles in physiology, aging, and calorie restrictionGenes & Development, 2006
- Histone deacetylases (HDACs): characterization of the classical HDAC familyBiochemical Journal, 2003
- The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell LymphomaNew England Journal of Medicine, 2002
- Histone deacetylases, transcriptional control, and cancerJournal of Cellular Physiology, 2000
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000